Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Oklahoma
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed locally advanced unresectable or borderline resectable adenocarcinoma of pancreas
Patients must have measurable disease as defined by RECIST 1.1 RECIST evaluations must have occurred within 4 weeks prior to study entry
No evidence of hepatic or pulmonary metastatic disease by CT or CT/PET scans
Male or non-pregnant and non-lactating female age \> or equal to 18 years and \< or equal to 70 years of age
Patient must have received no prior therapy for the treatment of locally advanced unresectable or borderline resectable pancreatic cancer
Patients must have adequate blood counts at baseline and blood chemistry levels
Patient has ECOG Performance Status 0 to 1
You may not be if
Patients with islet cell neoplasms excluded
Patients with known brain metastases
Therapeutic Coumadin for a history of pulmonary emboli or deep vein thrombosis (DVT)
Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
Known infection with HIV, hepatitis B or hepatitis C
Major surgery or vascular device placement within 4 weeks prior to Day 1 of treatment in study
Prior chemotherapy or radiation for pancreatic cancer
History of allergy or hypersensitivity to the study drugs
Patient is enrolled in any other clinical protocol or investigational trial
Metastatic disease on radiological staging
Prior malignancy within last 3 years
Significant cardiac disease
Any prior gastrointestinal (GI) disease or history of prior pelvic or abdominal radiation in which in opinion of the investigator may place the patient at increased risk
peripheral sensory neuropathy \> or equal to grade 2 at baseline
Clareo Health | FOLFIRINOX in Patients With Inoperable Pancreatic Cancer
